vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and MERCANTILE BANK CORP (MBWM). Click either name above to swap in a different company.

MERCANTILE BANK CORP is the larger business by last-quarter revenue ($67.6M vs $38.3M, roughly 1.8× ImmunityBio, Inc.). MERCANTILE BANK CORP runs the higher net margin — 33.6% vs -161.8%, a 195.4% gap on every dollar of revenue.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Tamilnad Mercantile Bank Limited (TMB) is an Indian bank headquartered at Thoothukudi, Tamil Nadu. TMB was founded in 1921 as the Nadar Bank, but changed its name to Tamilnad Mercantile Bank in November 1962 to widen its appeal beyond the Nadar community. The bank currently has 600 full branches throughout India, 12 regional offices and two link offices, two central processing centres, one service branch, four currency chests, 48 eLobby centres, 262 cash recycler machines and 1151 automated ...

IBRX vs MBWM — Head-to-Head

Bigger by revenue
MBWM
MBWM
1.8× larger
MBWM
$67.6M
$38.3M
IBRX
Higher net margin
MBWM
MBWM
195.4% more per $
MBWM
33.6%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
MBWM
MBWM
Revenue
$38.3M
$67.6M
Net Profit
$-61.9M
$22.7M
Gross Margin
99.0%
Operating Margin
-169.0%
Net Margin
-161.8%
33.6%
Revenue YoY
407.0%
Net Profit YoY
-4.7%
16.1%
EPS (diluted)
$-0.06
$1.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
MBWM
MBWM
Q1 26
$67.6M
Q4 25
$38.3M
$62.1M
Q3 25
$32.1M
$62.4M
Q2 25
$26.4M
$60.9M
Q1 25
$16.5M
$57.3M
Q4 24
$7.6M
$58.5M
Q3 24
$6.1M
$58.0M
Q2 24
$56.8M
Net Profit
IBRX
IBRX
MBWM
MBWM
Q1 26
$22.7M
Q4 25
$-61.9M
$22.8M
Q3 25
$-67.3M
$23.8M
Q2 25
$-92.6M
$22.6M
Q1 25
$-129.6M
$19.5M
Q4 24
$-59.2M
$19.6M
Q3 24
$-85.7M
$19.6M
Q2 24
$18.8M
Gross Margin
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Operating Margin
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
-169.0%
42.0%
Q3 25
-173.5%
44.0%
Q2 25
-269.8%
42.6%
Q1 25
-390.1%
42.0%
Q4 24
-919.0%
39.7%
Q3 24
-1314.3%
42.4%
Q2 24
41.4%
Net Margin
IBRX
IBRX
MBWM
MBWM
Q1 26
33.6%
Q4 25
-161.8%
36.8%
Q3 25
-209.8%
38.1%
Q2 25
-350.3%
37.1%
Q1 25
-784.9%
34.1%
Q4 24
-783.4%
33.5%
Q3 24
-1404.0%
33.8%
Q2 24
33.1%
EPS (diluted)
IBRX
IBRX
MBWM
MBWM
Q1 26
$1.32
Q4 25
$-0.06
$1.41
Q3 25
$-0.07
$1.46
Q2 25
$-0.10
$1.39
Q1 25
$-0.15
$1.21
Q4 24
$-0.08
$1.20
Q3 24
$-0.14
$1.22
Q2 24
$1.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
MBWM
MBWM
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
$1.5M
Stockholders' EquityBook value
$-500.5M
$736.9M
Total Assets
$501.9M
$6.9B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Total Debt
IBRX
IBRX
MBWM
MBWM
Q1 26
$1.5M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
IBRX
IBRX
MBWM
MBWM
Q1 26
$736.9M
Q4 25
$-500.5M
$724.9M
Q3 25
$-524.3M
$657.6M
Q2 25
$-570.7M
$631.5M
Q1 25
$-591.4M
$608.3M
Q4 24
$-489.1M
$584.5M
Q3 24
$-745.1M
$583.3M
Q2 24
$551.2M
Total Assets
IBRX
IBRX
MBWM
MBWM
Q1 26
$6.9B
Q4 25
$501.9M
$6.8B
Q3 25
$519.0M
$6.3B
Q2 25
$402.1M
$6.2B
Q1 25
$303.8M
$6.1B
Q4 24
$382.9M
$6.1B
Q3 24
$364.6M
$5.9B
Q2 24
$5.6B
Debt / Equity
IBRX
IBRX
MBWM
MBWM
Q1 26
0.00×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
MBWM
MBWM
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
$-70.4M
$18.0M
Q3 25
$-68.9M
$23.1M
Q2 25
$-79.7M
$-7.8M
Q1 25
$-85.9M
$-3.0M
Q4 24
$-85.1M
$101.1M
Q3 24
$-98.8M
$-8.1M
Q2 24
$9.1M
Free Cash Flow
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
FCF Margin
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Capex Intensity
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Cash Conversion
IBRX
IBRX
MBWM
MBWM
Q1 26
Q4 25
0.79×
Q3 25
0.97×
Q2 25
-0.35×
Q1 25
-0.15×
Q4 24
5.15×
Q3 24
-0.41×
Q2 24
0.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

MBWM
MBWM

Net Interest Income$55.9M83%
Noninterest Income$11.7M17%

Related Comparisons